CCL20 chemokine and other proinflammatory markers after Ad26.COV2.S vaccination
View abstract on PubMed
Summary
This summary is machine-generated.This study found no significant changes in C-C motif ligand 20 (CCL20) or IL-6 after Ad26.COV2.S vaccination. However, C-reactive protein (CRP) levels and anti-SARS-CoV-2 antibodies did change, with CRP differences noted in hypertensive patients.
Area Of Science
- Immunology
- Vaccinology
Background
- Biomarkers of vaccine-induced immunity are crucial during pandemics like COVID-19.
- Assessing C-C motif ligand 20 (CCL20) alongside other inflammatory markers provides insights into immune responses.
Purpose Of The Study
- To determine CCL20 concentration post-Ad26.COV2.S vaccination and its correlation with inflammatory molecules and anti-SARS-CoV-2 antibodies.
- To investigate inflammatory and immunologic differences between hypertensive and non-hypertensive individuals post-vaccination.
Main Methods
- 84 subjects vaccinated with Ad26.COV2.S were studied.
- CCL20, IL-6, and CRP levels were measured pre-vaccination and at 7 and 14 days post-vaccination.
- Anti-SARS-CoV-2 IgG antibody concentrations were measured at 7 and 14 days post-vaccination.
Main Results
- No statistically significant changes in CCL20 or IL-6 concentrations were observed post-vaccination.
- Significant differences were found in C-reactive protein (CRP) (P = 0.006) and anti-SARS-CoV-2 IgG antibody (P < 0.001) levels over time.
- CCL20 did not correlate with IL-6, CRP, or anti-SARS-CoV-2 IgG antibody levels.
- Hypertensive subjects showed a statistically significant difference in CRP concentration (P = 0.025) over the three time points.
Conclusions
- The study did not demonstrate changes in CCL20 concentration after Ad26.COV2.S vaccination, potentially due to the study's timeframe.
- Further research into chemokine profiles following SARS-CoV-2 immunization is needed to identify specific response patterns to vaccines.

